Form 4 for AVTR Avantor, Inc.
Accepted 2023-02-27 00:00:00 ET · period of report 2023-02-23 · accession 0001722482-23-000075 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-27 | 2023-02-23+ | AVTR | Brophy Gerard | EVP, Biopharma Production | F - Tax | $24.61 | -3,933 | 115.7K | -3% | -$96.8K |
| D | 2023-02-27 | 2023-02-24 | AVTR | Brophy Gerard | EVP, Biopharma Production | A - Grant | $0.00 | +20.3K | 117.7K | +21% | $0 |
| D | 2023-02-27 | 2023-02-24 | AVTR | Brophy Gerard | EVP, Biopharma Production | A - Grant | $0.00 | +49.2K | 49.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-23 | F | D | 1,893 | $24.59 | 97,420 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-24 | A | A | 20,308 | $0.00 | 117,728 | D | — | — | |
| 3 | Common | Common Stock | 2023-02-25 | F | D | 2,040 | $24.62 | 115,688 | D | — | — | |
| 4 | Derivative | Stock Options (Right to Buy) | 2023-02-24 | A | A | 49,215 | $0.00 | 49,215 | D | $24.62 · — to 2033-02-24 | 49,215 Common Stock | (F3) Reflects a grant of stock options that vest in four equal annual installments beginning on February 24, 2024. |